Visit CES booth 73710 for Live Audience Cycling Competition
IRVINE, Calif.--(BUSINESS WIRE)--Jan. 6, 2016--
Masimo
(NASDAQ: MASI) announced today that it has added a new parameter,
respiration rate from the pleth (RRp™), to its MightySat fingertip pulse
oximeter. MightySat is intended for general wellness and health
applications including sports, fitness, and relaxation management.
Respiration rate, or the number of breaths per minute, is infrequently
measured outside of healthcare settings because it typically requires
manual counting of breaths with a timer and then multiplying to convert
to a per minute rate, or chest leads or straps that are not convenient
to use. Fingertip pulse oximeters are being increasingly used for
general wellness and health applications. Now consumers will be able to
quickly and easily measure respiration rate, in addition to arterial
oxygen saturation (SpO2), pulse rate (PR), perfusion index
(PI), and Plethysmograph Variability Index (PVI®).
Masimo pulse oximeters are #1 in U.S. hospitals1 because they
provide accurate measurements when other pulse oximeters fail, by using
a revolutionary invention called Signal Extraction Technology (SET®).
MightySat features hospital-grade SET pulse oximetry and also provides
parameters not available on other fingertip pulse oximeters, such as RRp
and PVI. In addition, MightySat offers a Bluetooth wireless interface to
the Masimo Personal Health and Apple Health App to track, trend, and
communicate measurements. MightySat is increasingly being used by elite
athletes and teams to assess and improve performance.
“The addition of respiration rate to the MightySat is a game changer
because we can now quantify breathing - a fundamental indicator of
health, wellness, and sports performance,” stated Olympic Silver
Medalist Dotsie Bausch.
“Sometimes matches are won by a few points, and I need every breath to
count,” said Coco Vandeweghe, Professional Tennis Player on the WTA
Tour. “MightySat makes breath tracking easier.”
“We believe the MightySat will help transform the wearables market by
providing fitness enthusiasts with the same valuable personal data that
to date has only been available to elite athletes,” said Joe Kiani,
Chairman and CEO of Masimo.
“Helping athletes to improve their overall performance ecosystem is what
I do,” stated Tim DiFrancesco, PT, DPT, ATC, CSCS, Head Strength and
Conditioning Coach for the Los Angeles Lakers. “That requires gaining
insight into the well-being of the person as well as the physiology
within the person. Many objective monitoring tools fail to provide
accurate and valuable information in a swift and noninvasive manner, but
MightySat succeeds. After incorporating MightySat into my athlete
monitoring toolbox, I see an impressive list of potential value through
quantifying and measuring markers that give a more granular look at
athlete readiness, fatigue/overtraining, fuel source utilization, and
cardiovascular conditioning.”
This year at the Sands Expo in Las Vegas, attendees can visit Masimo at
CES booth 73710 and observe MightySat measurements before and after a
live audience cycling competition. Cycling participants will be aided by
two experts, Stig Severinsen and Dotsie Bausch. Stig is a four-time
World Champion freediver and holds multiple Guinness World Records,
including history’s longest breath-hold, of 22 minutes. Dotsie is a
seven-time USA Cycling National Champion, two-time Pan-American
Champion, and silver medalist in team pursuit cycling at the 2012 London
Olympics. Both Stig and Dotsie will also be available in the booth to
answer questions about how they have incorporated MightySat into their
health and fitness routines.
MightySat is available for purchase on Amazon U.S. and Amazon U.K.
MightySat with Respiration Rate will be available for purchase by the
end of February 2016.
@MasimoInnovates | #Masimo
References
-
iData Research. U.S. Market for Patient Monitoring Equipment. 2014.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. The benefits of Masimo SET® have
been proven in more than 100 independent and objective studies and it is
estimated to be used on more than 100 million patients in leading
hospitals and other healthcare settings around the world. In 2005,
Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total hemoglobin
(SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and more recently, Pleth Variability Index
(PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate,
and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive
patient monitoring and connectivity platform designed to speed the pace
of innovation and reduce the cost of care. Masimo is also taking an
active leadership role in mHealth with products such as the MightySat™
fingertip pulse oximeter. Additional information about Masimo and its
products may be found at www.masimo.com.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, those related to the expected adoption
of MightySat. These forward-looking statements are based on current
expectations about future events affecting us and are subject to risks
and uncertainties, all of which are difficult to predict and many of
which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our belief that Masimo's
unique noninvasive measurement technologies contribute to positive
clinical outcomes and patient safety; risks related to our belief that
Masimo noninvasive medical breakthroughs provide cost-effective
solutions with comparable accuracy and unique advantages; as well as
other factors discussed in the "Risk Factors" section of our most recent
reports filed with the Securities and Exchange Commission ("SEC"),
which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160106005840/en/
Source: Masimo
Masimo
Irene Paigah
(858) 859-7001
irenep@masimo.com